Learn More
Gibco™ PeproGMP® Human VEGF-165 Recombinant Protein, PeproTech®
Recombinant Protein
7100.00 SEK - 77600.00 SEK
Specifications
Accession Number | P15692 |
---|---|
For Use With (Application) | Functional Assay |
Format | Lyophilized |
Formulation | protein with no preservative |
Gene ID (Entrez) | 7422 |
Product Code | Brand | Quantity | Price | Quantity & Availability | |||||
---|---|---|---|---|---|---|---|---|---|
Product Code | Brand | Quantity | Price | Quantity & Availability | |||||
30275722
|
Gibco™
GMP100-20-1MG |
1 mg |
77600.00 SEK
1mg |
Please sign in to purchase this item. Need a web account? Register with us today! | |||||
30275491
|
Gibco™
GMP100-20-100UG |
100 ÎĽg |
11870.00 SEK
100µg |
Please sign in to purchase this item. Need a web account? Register with us today! | |||||
30275000
|
Gibco™
GMP100-20-50UG |
50 ÎĽg |
7100.00 SEK
50µg |
Please sign in to purchase this item. Need a web account? Register with us today! | |||||
Description
Recombinant Human VEGF 165 is a 38.2 kDa, disulfide-linked homodimeric protein consisting of two 165 amino acid polypeptide chains. Additional product information and specifications are provided on the Certificate of Analysis. All PeproGMP® products are manufactured using animal-derived component free materials. Product Description/Intended Use: PeproTech GMP recombinant proteins are manufactured for use as ancillary materials by applying applicable principles of GMP and quality control requirements from USP (United States Pharmacopeia) Chapter 1043 Ancillary Materials for Cell, Gene, and Tissue-Engineered Products. Product use statement: For research use or further manufacturing. Not for diagnostic use or direct administration into humans or animals.
The vascular endothelial growth factor (VEGF) family currently includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and PIGF. VEGF and its receptor system have been shown to be the fundamental regulators in the cell signaling of angiogenesis. Most tumors have the absolute requirement of angiogenesis and VEGF has been described as the most potent angiogenic cytokine linked to this process. To date 5 different isoforms of VEGF have been described. These isoforms are generated as the result of alternative splicing from a single VEGF gene. These various isoforms have been shown to bind to two tyrosine-kinase receptors flt-1 (VEGFR-1) and flk-1/KDR (VEGFR-2), which have been found to be expressed almost exclusively on endothelial cells.Specifications
P15692 | |
Lyophilized | |
7422 | |
PeproGMP™ Human VEGF-165 | |
<0.1 EU/ ÎĽg | |
VEGF-165 | |
Unconjugated | |
APMAEGGGQN HHEVVKFMDV YQRSYCHPIE TLVDIFQEYP DEIEYIFKPS CVPLMRCGGC CNDEGLECVP TEESNITMQI MRIKPHQGQH IGEMSFLQHN KCECRPKKDR ARQENPCGPC SERRKHLFVQ DPQTCKCSCK NTDSRCKARQ LELNERTCRC DKPRR | |
Determined by the proliferation of HUVECs. | |
Lyophilized |
Functional Assay | |
protein with no preservative | |
38.2 kDa | |
RUO | |
H-VEGF-165; MVCD1; M-VEGF-165; vascular endothelial growth factor 165 b; vascular endothelial growth factor A; vascular endothelial growth factor A121; vascular endothelial growth factor A165; vascular permeability factor; VEGF; VEGF164; VEGF165; Vegfa; VEGF-A; VPF | |
Determined by the proliferation of HUVECs. | |
Recombinant | |
-20°Cor to +80°C if preferred | |
E. coli | |
≥ 98% by SDS-PAGE gel and HPLC analyses. |
Your input is important to us. Please complete this form to provide feedback related to the content on this product.